Stryker Corporation (SYK) Total Return:-16.86%(TTM)
Over the latest trailing 12-month period, Stryker Corporation (SYK)'s total return cagr is -16.86%. The comparable SPY value is +25.93%. Year-to-date total return is -11.40%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in SYK
$624,566
(62.5x return)
Invested on Jun 17, 1996
Growth of $10,000 in SPY (S&P 500)
$188,641
(18.9x return)
Invested on Jun 17, 1996
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
-11.4%
1-Year Total Return
-16.9%
Current Dividend Yield
1.11%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | (17.7%) | (16.9%) | +0.8% |
| 3 Years | +1.8% | +2.8% | +1.0% |
| 5 Years | +3.9% | +5.0% | +1.1% |
| 10 Years | +10.5% | +11.7% | +1.2% |
| 15 Years | +11.8% | +13.2% | +1.4% |
| 20 Years | +10.1% | +11.4% | +1.3% |
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo